Clinical characteristics
| Characteristic . | Relapse during/after chemotherapy . | Relapse after SCT . | P . | Total . |
|---|---|---|---|---|
| n* | 378 | 169 | 547 | |
| Age† | ||||
| Median age, y | 32 | 34 | > .05 | 33 |
| 15-25 | 129 (34%) | 50 (30%) | 179 (33%) | |
| 26-45 | 173 (46%) | 84 (50%) | 257 (47%) | |
| 46-55 | 76 (20%) | 35 (20%) | 111 (20%) | |
| Sex | ||||
| Male | 242 (64%) | 101 (60%) | > .05 | 343 (63%) |
| Female | 136 (36%) | 68 (40%) | 204 (37%) | |
| WBCs/μL† | ||||
| < 30 000 | 250 (69%) | 100 (62%) | > .05 | 350 (67%) |
| > 30 000 | 113 (31%) | 61 (38%) | 174 (33%) | |
| Immunophenotype† | ||||
| Pro-B | 18 (5%) | 18 (11%) | < .0001 | 36 (7%) |
| Pre-B/c | 253 (67%) | 104 (62%) | 357 (66%) | |
| Early T | 12 (3%) | 33 (20%) | 45 (8%) | |
| Mature T | 16 (4%) | 11 (7%) | 27 (5%) | |
| Thymic | 77 (20%) | 1 (1%) | 78 (14%) | |
| Risk group† | ||||
| Standard | 258 (68%) | 14 (8%) | < .0001 | 272 (50%) |
| High | 87 (23%) | 94 (56%) | 181 (33%) | |
| Very high (Ph+) | 33 (9%) | 61 (36%) | 94 (17%) | |
| Time from diagnosis to relapse, mo | ||||
| Median (range, d) | 288 (22-2838) | 122 (19-666) | < .0001 | 162 (19-2838) |
| < 18 | 268 (71%) | 164 (97%) | 432 (79%) | |
| > 18 | 110 (29%) | 5 (3%) | 115 (21%) | |
| Site of relapse | ||||
| BM only ± other | 317 (89%) | 111 (85%) | > .05 | 428 (88%) |
| BM ± CNS ± other | 12 (3%) | 6 (5%) | 18 (4%) | |
| Isolated CNS | 7 (2%) | 4 (3%) | 11 (2%) | |
| Isolated other extramedullary‡ | 22 (6%) | 10 (7%) | 32 (6%) |
| Characteristic . | Relapse during/after chemotherapy . | Relapse after SCT . | P . | Total . |
|---|---|---|---|---|
| n* | 378 | 169 | 547 | |
| Age† | ||||
| Median age, y | 32 | 34 | > .05 | 33 |
| 15-25 | 129 (34%) | 50 (30%) | 179 (33%) | |
| 26-45 | 173 (46%) | 84 (50%) | 257 (47%) | |
| 46-55 | 76 (20%) | 35 (20%) | 111 (20%) | |
| Sex | ||||
| Male | 242 (64%) | 101 (60%) | > .05 | 343 (63%) |
| Female | 136 (36%) | 68 (40%) | 204 (37%) | |
| WBCs/μL† | ||||
| < 30 000 | 250 (69%) | 100 (62%) | > .05 | 350 (67%) |
| > 30 000 | 113 (31%) | 61 (38%) | 174 (33%) | |
| Immunophenotype† | ||||
| Pro-B | 18 (5%) | 18 (11%) | < .0001 | 36 (7%) |
| Pre-B/c | 253 (67%) | 104 (62%) | 357 (66%) | |
| Early T | 12 (3%) | 33 (20%) | 45 (8%) | |
| Mature T | 16 (4%) | 11 (7%) | 27 (5%) | |
| Thymic | 77 (20%) | 1 (1%) | 78 (14%) | |
| Risk group† | ||||
| Standard | 258 (68%) | 14 (8%) | < .0001 | 272 (50%) |
| High | 87 (23%) | 94 (56%) | 181 (33%) | |
| Very high (Ph+) | 33 (9%) | 61 (36%) | 94 (17%) | |
| Time from diagnosis to relapse, mo | ||||
| Median (range, d) | 288 (22-2838) | 122 (19-666) | < .0001 | 162 (19-2838) |
| < 18 | 268 (71%) | 164 (97%) | 432 (79%) | |
| > 18 | 110 (29%) | 5 (3%) | 115 (21%) | |
| Site of relapse | ||||
| BM only ± other | 317 (89%) | 111 (85%) | > .05 | 428 (88%) |
| BM ± CNS ± other | 12 (3%) | 6 (5%) | 18 (4%) | |
| Isolated CNS | 7 (2%) | 4 (3%) | 11 (2%) | |
| Isolated other extramedullary‡ | 22 (6%) | 10 (7%) | 32 (6%) |
Total number of patients may vary for the different subgroups depending on the number of patients with evaluable data.
At first diagnosis.
Locations of extramedullary involvement were: mediastinum (n = 6), testis (n = 5), lymph nodes (n = 5), breast (n = 4), skin (n = 4), bone (n = 3), kidney (n = 2), liver (n = 2), nasopharynx/tonsils (n = 2), pleura/pericardium (n = 2), prostate (n = 1), paravertebral (n = 1), epidural (n = 1), parotis (n = 1), retina (n = 1), and lung (n = 1).